COPENHAGEN, Denmark, May 24, 2012 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today a milestone payment of DKK 20 million from GlaxoSmithKline to Genmab in connection with the filing of the New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW). The NDA is for Arzerra® (ofatumumab) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.
